Researcher honored for work developing new treatments for prostate cancer

UCLA cancer researcher Andrew Goldstein and his lab team
UCLA cancer researcher Andrew Goldstein (center) with members of his lab

Andrew Goldstein, an assistant professor of molecular, cell and developmental biology and urology at the David Geffen School of Medicine at UCLA, will be honored by the American Cancer Society with its Giants of Science Hope award.

The award is given to a researcher of great promise who is working in a critical area of cancer research. Goldstein, a member of the UCLA Jonsson Comprehensive Cancer Center and the UCLA Broad Stem Cell Research Center, and his laboratory studies the cellular and molecular basis of prostate cancer. He is working to find new treatments for castration-resistant prostate cancer, the most advanced stage of the disease. His research is also focused on identifying and understanding the mechanisms of prostate cancer initiation and progression.

His recent work, which is in part funded by the American Cancer Society, addresses the effects of inflammation on progenitor cells that can initiate cancer and the role of the molecule CD38 in the creation of prostate tumors. Through understanding how these cells and molecules work, Goldstein hopes to help find new targeted treatments for advanced prostate cancer.

Goldstein will accept the award at the organization’s annual research award gala on Oct. 18 in Beverly Hills.

Along with funding from the American Cancer Society, Goldstein’s research is supported by the Margaret E. Early Medical Research Trust and STOP Cancer.